These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

274 related items for PubMed ID: 29961975

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia.
    Ushakova O, Sokolovskaya V, Morozova A, Valeeva F, Zanozina O, Sazonova O, Zhadanova E, Starceva M, Kazakova E, Saifullina M, Shapiro I, Tarasov A, Al-Tayar B, Starkova N.
    Clin Ther; 2007 Nov; 29(11):2374-84. PubMed ID: 18158078
    [Abstract] [Full Text] [Related]

  • 3. The study of once- and twice-daily biphasic insulin aspart 30 (BIAsp 30) with sitagliptin, and twice-daily BIAsp 30 without sitagliptin, in patients with type 2 diabetes uncontrolled on sitagliptin and metformin-The Sit2Mix trial.
    Linjawi S, Sothiratnam R, Sari R, Andersen H, Hiort LC, Rao P.
    Prim Care Diabetes; 2015 Oct; 9(5):370-6. PubMed ID: 25488587
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Subject-driven titration of biphasic insulin aspart 30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial.
    Yang W, Zhu L, Meng B, Liu Y, Wang W, Ye S, Sun L, Miao H, Guo L, Wang Z, Lv X, Li Q, Ji Q, Zhao W, Yang G.
    J Diabetes Investig; 2016 Jan; 7(1):85-93. PubMed ID: 26816605
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Composite cardiovascular risk and BMI affected comparative profiles of BIAsp 30 + metformin vs BIAsp 30 monotherapy: a MERIT post-hoc analysis.
    Guo L, Chang B, Chen L, Yang L, Liu Y, Feng B, He Q.
    Sci Rep; 2021 Feb 18; 11(1):4131. PubMed ID: 33602996
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy and safety of insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Chinese adults with type 2 diabetes: A phase III, open-label, 2:1 randomized, treat-to-target trial.
    Yang W, Ma J, Hong T, Liu M, Miao H, Peng Y, Wang C, Xu X, Yang T, Nielsen AM, Pan L, Liu W, Zhao W.
    Diabetes Obes Metab; 2019 Jul 18; 21(7):1652-1660. PubMed ID: 30869183
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Initiating or switching to biphasic insulin aspart 30 in type 2 diabetes patients from Algeria: a sub-analysis of the A₁chieve study.
    Lezzar A, Ayad F, Dahaoui A, Salah-Mansour A, Berrouiguet AY.
    Diabetes Res Clin Pract; 2013 Aug 18; 101 Suppl 1():S37-44. PubMed ID: 23958570
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of three-times-daily versus twice-daily biphasic insulin aspart 30 in patients with type 2 diabetes mellitus inadequately controlled with basal insulin combined with oral antidiabetic drugs.
    Yang W, Ersoy C, Wang G, Ye S, Liu J, Miao H, Asirvatham A, Werther S, Kadu P, Chow F.
    Diabetes Res Clin Pract; 2019 Apr 18; 150():158-166. PubMed ID: 30872064
    [Abstract] [Full Text] [Related]

  • 18. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes.
    Cucinotta D, Smirnova O, Christiansen JS, Kanc K, le Devehat C, Wojciechowska M, López de la Torre M, Liebl A.
    Diabetes Obes Metab; 2009 Jul 18; 11(7):700-8. PubMed ID: 19476479
    [Abstract] [Full Text] [Related]

  • 19. Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results.
    Nobels F, D'Hooge D, Crenier L.
    Curr Med Res Opin; 2012 Jun 18; 28(6):1017-26. PubMed ID: 22612579
    [Abstract] [Full Text] [Related]

  • 20. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
    Raskin P, Matfin G, Schwartz SL, Chaykin L, Chu PL, Braceras R, Wynne A.
    Diabetes Obes Metab; 2009 Jan 18; 11(1):27-32. PubMed ID: 17941873
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.